Alumis Inc

ALMS

Alumis Inc is a healthcare company that specializes in developing treatments for immune dysregulation. The company is focused on providing innovative therapeutic solutions to address various immune system-related conditions.

CCI Score

30.00

April 7

Latest Event

Alumis Inc Enters Licensing Agreement with Kaken Pharmaceuticals

On March 25, 2025, Alumis Inc announced a collaboration and licensing agreement with Kaken Pharmaceuticals. Under the agreement, Alumis is licensing its drug candidate ESK-001, aimed at treating immune dysregulation, for development, manufacturing, and commercialization in Japan with a focus on dermatologic applications.

Take Action

So what can you do? Support by shopping, spreading the word, or offering your support.

Shop Alternatives SEE ALL: VivoPower

Intellias

NIAR
Use Your Voice OTHER TOOLS
Investigate
Share the Score SUPPORT CCI

DISSENTER

Alumis Inc is currently rated as a Dissenter.

+25 to +44 CCI Score

These companies are vocal in their opposition to authoritarian regimes. They publicly criticize oppressive policies and engage in advocacy efforts to promote accountability and transparency, even if their actions aren’t as extensive as those of Moral Leaders.

Latest Events

MAR

25

2025

Alumis Inc Enters Licensing Agreement with Kaken Pharmaceuticals
30.00

On March 25, 2025, Alumis Inc announced a collaboration and licensing agreement with Kaken Pharmaceuticals. Under the agreement, Alumis is licensing its drug candidate ESK-001, aimed at treating immune dysregulation, for development, manufacturing, and commercialization in Japan with a focus on dermatologic applications.